bio

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025 17:00 ET  | Source: TELA Bio, Inc. MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio,…

5 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

August 04, 2025 08:05 ET  | Source: MaxCyte, Inc MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of…

5 months ago

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimers Association International Conference

July 24, 2025 07:00 ET  | Source: INmune Bio, Inc. Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio…

5 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:00 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

6 months ago

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 07, 2025 08:00 ET  | Source: KALA BIO, Inc. ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO,…

6 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

6 months ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:05 ET  | Source: TELA Bio, Inc. MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio,…

7 months ago

Vanqua Bio to Present at Upcoming Scientific Conferences

CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim…

7 months ago